Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi

Ticks and Tick-borne Diseases

Volumn 1, Issue 1, 2010, Pages 30-34

  Ates, Louis ^a   Hanssen Hübner, Christa ^b   Norris, Douglas E ^c   Richter, Dania ^d   Kraiczy, Peter ^a   Hunfeld, Klaus Peter ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Academic Teaching Hospital   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Borrelia burgdorferi; Lyme borreliosis; Susceptibility testing; Tetracyclines; Tigecycline

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; DOXYCYCLINE; GLYCYLGLYCINE; TETRACYCLINE; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIOSTASIS; BACTERIUM ISOLATION; BORRELIA BURGDORFERI; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; IN VITRO STUDY; INCUBATION TIME; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECIES DIFFERENCE; SPIROCHETE;

ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; TETRACYCLINE; TIME FACTORS;

BORRELIA; BORRELIA AFZELII; BORRELIA BURGDORFERI; NEGIBACTERIA; POSIBACTERIA; SPIROCHAETALES;

EID: 77949336910     PISSN: 1877959X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ttbdis.2009.11.004     Document Type: Article

References (33)

1. Belfaiza J., Postic D., Bellenger E., Baranton G., and Girons I.S. Genomic fingerprinting of Borrelia burgdorferi sensu lato by pulsed-field gel electrophoresis. J. Clin. Microbiol. 31 (1993) 2873-2877
2. Bunikis I., Denker K., Ostberg Y., Andersen C., Benz R., and Bergström S. An RND-type efflux system in Borrelia burgdorferi is involved in virulence and resistance to antimicrobial compounds. PLoS Pathog. 4 (2008) e1000009
3. CLSI, 2006. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved standard, Seventh ed., M7-A7. CLSI, Wayne, Pa.
4. Chau S.L., Chu Y.W., and Houang E.T. Novel resistance-nodulation-cell division efflux system AdeDE in Acinetobacter genomic DNA group 3. Antimicrob. Agents Chemother. 48 (2004) 4054-4055
5. Greer N.D. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics: Bayl. Univ. Med. Cent. Proc. 19 (2006) 155-161
6. Hodzic E., Feng S., Holden K., Freet K.J., and Barthold S.W. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob. Agents Chemother. 52 (2008) 1728-1736
7. Hunfeld K.-P., and Brade V. Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: What we know, what we don't know, and what we need to know. Wien Klin Wochenschr. 118 (2006) 659-668
8. Hunfeld K.-P., Kraiczy P., Wichelhaus T.A., Schäfer V., and Brade V. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int. J. Antimicrob. Agents 15 (2000) 11-17
9. Hunfeld K.-P., Kraiczy P., Wichelhaus T.A., Schäfer V., and Brade V. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur. J. Clin. Microbiol. Infect. Dis. 19 (2000) 27-32
10. Hunfeld K.-P., Rodel R., and Wichelhaus T.A. In vitro activity of eight oral cephalosporins against Borrelia burgdorferi. Int. J. Antimicrob. Agents 21 (2003) 313-318
11. Hunfeld K.-P., Ružić-Sabljić E., Norris D.E., Kraiczy P., and Strle F. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob. Agents Chemother. 49 (2005) 1294-1301
12. Hunfeld K.-P., Wichelhaus T.A., Kekoukh E., Molitor M., Kraiczy P., and Brade V. In vitro susceptibility of the Borrelia burgdorferi sensu lato complex to ABT-773, a novel ketolide. J. Antimicrob. Chemother. 48 (2001) 447-449
13. Jamal W.Y., Al Hashem G., Khodakhast F., and Rotimi V.O. Comparative in vitro activity of tigecycline and nine other antibiotics against gram-negative bacterial isolates, including ESBL-producing strains. J. Chemother. 21 (2009) 261-266
14. Kaiser R. Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone. Nervenarzt 75 (2004) 553-557 (in German)
15. Kraiczy P., Weigand J., Wichelhaus T.A., Heisig P., Backes H., Schäfer V., Acker G., Brade V., and Hunfeld K.-P. In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 45 (2001) 2486-2494
16. Ljostad U., Skogvoll E., Eikeland R., Midgard R., Skarpaas T., Berg A., and Mygland A. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 7 (2008) 690-695
17. Loewen P.S., Marra C.A., and Marra F. Systematic review of the treatment of early Lyme disease. Drugs 57 (1999) 157-173
18. Margos G., Vollmer S.A., Cornet M., Garnier M., Fingerle V., Wilske B., Bormane A., Vitorino L., Collares-Pereira M., Drancourt M., and Kurtenbach K. A new Borrelia species defined by multilocus sequence analysis of housekeeping genes. Appl. Environ. Microbiol. 75 (2009) 5410-5416
19. Miklossy J., Kasas S., Zurn A.D., McCall S., Yu S., and McGeer P.L. Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J. Neuroinflammation. 5 (2008) 40
20. Morgenstern K., Baljer G., Norris D.E., Kraiczy P., Hanssen-Hübner C., and Hunfeld K.-P. In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. Antimicrob. Agents Chemother. 53 (2009) 1281-1284
21. Patel I.H., and Kaplan S.A. Pharmacokinetic profile of ceftriaxone in man. Am. J. Med. 77 (1984) 17-25
22. Preac-Mursic V., Weber K., Pfister H.W., Wilske B., Gross B., Baumann A., and Prokop J. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 17 (1989) 355-359
23. Preac-Mursic, V., Wilske, B., Schierz, G., 1986. European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility: Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] 263, 112-118.
24. Smith R.P., Schoen R.T., Rahn D.W., Sikand V.K., Nowakowski J., Parenti D.L., Holman M.S., Persing D.H., and Steere A.C. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann. Intern. Med. 136 (2002) 421-428
25. Richter D., and Matuschka F.R. Perpetuation of the Lyme disease spirochete Borrelia lusitaniae by lizards. Appl. Environ. Microbiol. 72 (2006) 4627-4632
26. Stanek G., O'Connell S., Cimmino M., Aberer E., Kristoweritsch W., Granström M., Guy E., and Gray J. European Union concerted action on risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr. 108 (1996) 741-747
27. Steere A.C. Lyme disease. N. Engl. J. Med. 345 (2001) 115-125
28. Strle F., Cheng Y., Cimperman J., Maraspin V., Lotric-Furlan S., Nelson J.A., Picken M.M., Ružić-Sabljić E., and Picken R.N. Persistence of Borrelia burgdorferi sensu lato in resolved erythema migrans lesions. Clin. Infect. Dis. 21 (1995) 380-389
29. Weinstein A., and Britchkov M. Lyme arthritis and post-Lyme disease syndrome. Curr. Opin. Rheumatol. 14 (2002) 383-387
30. Wormser G.P., Ramanathan R., Nowakowski J., McKenna D., Holmgren D., Visintainer P., Dornbush R., Singh B., and Nadelman R.B. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 138 (2003) 697-704
31. Yang X., Nguyen A., Qiu D., and Luft B.J. In vitro activity of tigecycline against multiple strains of Borrelia burgdorferi. J. Antimicrob. Chemother. 63 (2009) 709-712
32. Zhanel G.G., Decorby M., Nichol K.A., Baudry P.J., Karlowsky J.A., Lagace-Wiens P.R., McCracken M., Mulvey M.R., and Hoban D.J. Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006). Can. J. Infect. Dis. Med. Microbiol. 19 (2008) 243-249
33. Zhanel G.G., Homenuik K., Nichol K., Noreddin A., Vercaigne L., Embil J., Gin A., Karlowsky J.A., and Hoban D.J. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64 (2004) 63-88